Literature DB >> 15388634

Diagnostic accuracy of ten second-generation (human) tissue transglutaminase antibody assays in celiac disease.

Britta Van Meensel1, Martin Hiele, Ilse Hoffman, Severine Vermeire, Paul Rutgeerts, Karel Geboes, Xavier Bossuyt.   

Abstract

BACKGROUND: Anti-tissue transglutaminase (tTG) assays that use human tTG as antigen have recently become available. We evaluated commercially available assays with human tTG antigen to estimate their diagnostic accuracies and to determine whether they agree sufficiently to be used interchangeably.
METHODS: Ten commercially available second-generation anti-tTG assays were evaluated. The following populations were studied: celiac disease (CD) patients at the time of diagnosis without (n = 70) or with (n = 5) IgA deficiency; diseased controls (n = 70); and CD patients without (n = 28) or with (n = 2) IgA deficiency during follow-up. All individuals included in the study underwent intestinal biopsy. Technical performance (linearity, interference, precision, correlation, and agreement) and diagnostic accuracy (sensitivity and specificity) were compared. Anti-gliadin and anti-endomysium antibodies were also measured.
RESULTS: IgA anti-tTG results correlated well overall, but numerical values differed. Diagnostic sensitivity ranged between 91% and 97% and specificity between 96% and 100%. These were higher than the sensitivity and specificity of the IgA endomysium assay and the IgA gliadin assay. Generally, IgG anti-tTG was less sensitive but more specific than IgG anti-gliadin for the diagnosis of CD in the small group of IgA-deficient patients.
CONCLUSIONS: Overall diagnostic performance of IgA tTG assays is acceptable and comparable among the different assays, but numerical values differ. Standardization is needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388634     DOI: 10.1373/clinchem.2004.035832

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  21 in total

1.  Factors that influence adherence to a gluten-free diet in adults with celiac disease.

Authors:  Daniel A Leffler; Jessica Edwards-George; Melinda Dennis; Detlef Schuppan; Francis Cook; Debra L Franko; Jessica Blom-Hoffman; Ciaran P Kelly
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

2.  Diagnostic efficacy of the ELISA test for the detection of deamidated anti-gliadin peptide antibodies in the diagnosis and monitoring of celiac disease.

Authors:  Elio Tonutti; Daniela Visentini; Alessia Picierno; Nicola Bizzaro; Danilo Villalta; Renato Tozzoli; Graziano Kodermaz; Antonio Carroccio; Giuseppe Iacono; Saverio Teresi; Stella Maria La Chiusa; Ignazio Brusca
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 3.  Screening for celiac disease in the general population and in high-risk groups.

Authors:  Jonas F Ludvigsson; Timothy R Card; Katri Kaukinen; Julio Bai; Fabiana Zingone; David S Sanders; Joseph A Murray
Journal:  United European Gastroenterol J       Date:  2015-04       Impact factor: 4.623

4.  Positive deamidated gliadin peptide antibodies and negative tissue transglutaminase IgA antibodies in a pediatric population: to biopsy or not to biopsy.

Authors:  Miriam Parizade; Bracha Shainberg
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

5.  Quality not quantity for transglutaminase antibody 2: the performance of an endomysial and tissue transglutaminase test in screening coeliac disease remains stable over time.

Authors:  K Swallow; G Wild; R Sargur; D S Sanders; I Aziz; A D Hopper; W Egner
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

6.  Hemolysis and IgA-antibodies against tissue transglutaminase: When are antibody test results no longer reliable?

Authors:  Johannes Wolf; Norman Haendel; Johannes Remmler; Carl Elias Kutzner; Thorsten Kaiser; Thomas Mothes
Journal:  J Clin Lab Anal       Date:  2017-11-23       Impact factor: 2.352

7.  Combination testing for antibodies in the diagnosis of coeliac disease: comparison of multiplex immunoassay and ELISA methods.

Authors:  S Rashtak; M W Ettore; H A Homburger; J A Murray
Journal:  Aliment Pharmacol Ther       Date:  2008-09-15       Impact factor: 8.171

8.  Performance of serology assays for diagnosing celiac disease in a clinical setting.

Authors:  Miriam Parizade; Yoram Bujanover; Batya Weiss; Vered Nachmias; Bracha Shainberg
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

9.  A report on the International Transglutaminase Autoantibody Workshop for Celiac Disease.

Authors:  Marcella Li; Liping Yu; Claudio Tiberti; Margherita Bonamico; Iman Taki; Dongmei Miao; Joseph A Murray; Marian J Rewers; Edward J Hoffenberg; Daniel Agardh; Patricia Mueller; Martin Stern; Ezio Bonifacio; Edwin Liu
Journal:  Am J Gastroenterol       Date:  2009-01       Impact factor: 10.864

10.  Do we need to measure total serum IgA to exclude IgA deficiency in coeliac disease?

Authors:  D Sinclair; M Saas; A Turk; M Goble; D Kerr
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.